BLUE
bluebird bio
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About BLUE
Bluebird Bio, Inc.
A company that develops therapeutics to treat severe genetic and orphan diseases using gene therapy
Biological Technology
04/16/1992
06/19/2013
NASDAQ Stock Exchange
248
12-31
Common stock
455 Grand Union Boulevard , Somerville, Massachusetts 02145
--
Bluebird bio, Inc., was incorporated in Delaware on April 16, 1992. The company was established to develop, manufacture and sell therapies to safely and effectively deliver genes that can be used to treat serious human diseases. They focus on researching, developing and commercializing potentially curative gene therapies for the treatment of serious genetic diseases based on their proprietary Lentiviral Vector (" LVV ") gene addition platform. They currently sell three gene therapies in the US: ZYNTEGLO (betibeglogene autoemcel, also known as beti-cel) and SKYSONA (elivaltogene autoemcel), approved by the U.S. Food and Drug Administration (" FDA ") in 2022, And LYFGENIA (lovotibegogene autoemcl, also known as lovo cel), which was approved by the U.S. Food and Drug Administration in December 2023.
Company Financials
EPS
BLUE has released its 2024 Q3 earnings. EPS was reported at -0.31, versus the expected -0.35, beating expectations. The chart below visualizes how BLUE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BLUE has released its 2024 Q4 earnings report, with revenue of 38.52M, reflecting a YoY change of 391.72%, and net profit of -28.71M, showing a YoY change of 64.48%. The Sankey diagram below clearly presents BLUE’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
